---
title: "Tyrosine kinase inhibitors-of-renal-cell-carcinoma"
date: "2024-01-03 11:11:04"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[renal-cell-carcinoma]]

# Tyrosine kinase inhibitors-of-renal-cell-carcinoma

\*\*1Â° endpoint(s) listed below include PFS &/or OS at interim analysis Class S/E: HTN, fatigue, diarrhea, stomatitis, nausea, hand-foot syn, skin/hair color changes â†“ LVEF, â†“ WBC, â†“ PLT, AST/ALT abnormalities, TFT abnormalities

Axitinib (Lancet 2011;378:1931) vs. sorafenib: PFS: 6.7 mos vs. 4.7 mos (HR: 0.665, P <0.0001)
Cabozantinib (NEJM 2015;373:1814) vs. everolimus: PFS 7.4 mos vs. 3.8 mos (HR: 0.58, P <0.001)
Pazopanib (JCO 2010;28:1061) vs. placebo: PFS: 9.2 mos vs. 4.2 mos (HR: 0.46, P <0.0001)
Sorafenib (NEJM 2007; 357:203) vs. placebo: OS: 78% vs. 73% (HR for death: 0.72, P = 0.02)
Sunitinib (NEJM 2007;356:115) vs. IFNÎ±: PFS 11 mos vs. 5 mos (HR: 0.42, P <0.001)

### Siblings

- [[Epidemiology-of-renal-cell-carcinoma]]
- [[Histology and molecular biology-of-renal-cell-carcinoma]]
- [[Hereditary RCC and germline testing-of-renal-cell-carcinoma]]
- [[Clinical presentation-of-renal-cell-carcinoma]]
- [[Staging (TNM classification) and prognosis-of-renal-cell-carcinoma]]
- [[Treatment principles-of-renal-cell-carcinoma]]
- [[Systemic therapy for metastatic clear cell RCC]]
- [[Second-line therapies-of-renal-cell-carcinoma]]
- [[Combined-modality therapies-of-renal-cell-carcinoma]]
- [[Tyrosine kinase inhibitors-of-renal-cell-carcinoma]]
- [[Immunotherapies-of-renal-cell-carcinoma]]
- [[mTOR inhibitors-of-renal-cell-carcinoma]]
- [[Non-clear cell histology-of-renal-cell-carcinoma]]

